The high selectivity of Pellino1 for phosphorylated STAT3 at the Y705 residue holds promise in the development of an important therapeutic strategy for IBD and CAC, potentially through interventions that can disrupt binding between Pellino1 and STAT3. Here, PELI1 is linked to inflammatory bowel disease.